经M6A修饰的lncRNA FAM83H-AS1通过PTBP1促进结直肠癌的进展
相关实验视频
Updated: Jun 22, 2025
04:20
Author Spotlight: Exploring the Role of FAM83A in Cervical Cancer
Published on: February 9, 2024
918
Xiao-Jing Luo1, Yun-Xin Lu2, Yun Wang2
1Department of Pathology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, 510060, PR China.
Cancer letters
|July 4, 2024
概括
研究人员确定FAM83H-AS1作为一个关键的长非编码RNA (lncRNA),促进结直肠癌 (CRC) 的生长和转移. 用ASO治疗准FAM83H-AS1在胃肠道癌症中显示出显著的疗效,特别是在与类药物结合时.
科学领域:
- 分子瘤学分子瘤学
- 在RNA生物学,RNA生物学.
- 癌症治疗方法 癌症治疗方法
背景情况:
- 长非编码RNAs (lncRNAs) 与癌症进展有关,但结直肠癌 (CRC) 的特定驱动因素仍然难以捉摸.
- 确定新的治疗点对于改善CRC治疗结果至关重要.
研究的目的:
- 识别和描述涉及结直肠癌 (CRC) 进展的新型 lncRNA.
- 研究FAM83H-AS1在CRC中的作用及其作为治疗点的潜力.
主要方法:
- 分析第四阶段的CRC组织和相邻的正常组织.
- 在体外和体内实验涉及FAM83H-AS1敲击和基于ASO的治疗.
- 研究M6A修饰和RNA结合蛋白相互作用 (PTBP1).
主要成果:
- 在CRC中,FAM83H-AS1被确定为促进瘤的lncRNA.
- FAM83H-AS1敲击抑制了CRC细胞的增殖和转移;过度表达促进了这些效应.
- 通过METTL3修改M6A和与PTBP1相互作用对于FAM83H-AS1功能至关重要.
- ASO-FAM83H-AS1抑制了GI瘤的生长,包括CRC,胃癌 (GC) 和食道状细胞癌 (ESCC).
- 与ASO-FAM83H-AS1和剂的联合治疗在肠道癌症中实现了病理完整的反应.
结论:
- FAM83H-AS1是CRC中的致癌性lncRNA,由M6A修饰和PTBP1.1调节.
- 向FAM83H-AS1代表了对肠道癌症的有希望的治疗策略,特别是在与基化疗相结合时.
相关概念视频
02:39lncRNA - Long Non-coding RNAs
8.5K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.5K
02:23Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
02:07Tumor Progression
6.3K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K
03:03mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
03:18Non-LTR Retrotransposons
11.5K
As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
11.5K
01:22MicroRNAs
3.0K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K